Tubeimoside I (CAS 102040-03-9)
See product citations (1)
QUICK LINKS
Tubeimoside I is extensively researched in the context of its biochemical properties and mechanisms of action in cell signaling and apoptosis pathways. This compound, derived from natural sources, is primarily utilized in studies focusing on its role in cellular regulation and signal transduction. Researchers investigate Tubeimoside I for its ability to modulate various signaling pathways that are in cellular health and disease states. This includes its effects on cytokine production and inflammatory responses within cells. Furthermore, Tubeimoside I is used in studies related to oxidative stress and its impact on cellular antioxidants, providing insights into the potential mechanisms through which cells respond to and manage oxidative damage.
Tubeimoside I (CAS 102040-03-9) References
- [Cell cycle arrest and apoptosis induced by tubeimoside in HeLa cell]. | Yang, P., et al. 2002. Ai Zheng. 21: 346-50. PMID: 12452008
- Inhibitory effects of tubeimoside I on synoviocytes and collagen-induced arthritis in rats. | Liu, Z., et al. 2018. J Cell Physiol. 233: 8740-8753. PMID: 29761884
- Tubeimoside I suppresses diabetes-induced bone loss in rats, osteoclast formation, and RANKL-induced nuclear factor-κB pathway. | Yang, M., et al. 2020. Int Immunopharmacol. 80: 106202. PMID: 32004923
- Tubeimoside I improves survival of mice in sepsis by inhibiting inducible nitric oxide synthase expression. | Luo, M., et al. 2020. Biomed Pharmacother. 126: 110083. PMID: 32272432
- Tubeimoside I Antagonizes Yoda1-Evoked Piezo1 Channel Activation. | Liu, S., et al. 2020. Front Pharmacol. 11: 768. PMID: 32523536
- Tubeimoside I induces autophagy in HepG2 cells by activating the AMP-activated protein kinase signaling pathway. | Ruan, C., et al. 2020. Oncol Lett. 20: 623-630. PMID: 32537027
- Tubeimoside I promotes angiogenesis via activation of eNOS-VEGF signaling pathway. | Yang, X., et al. 2021. J Ethnopharmacol. 267: 113642. PMID: 33264658
- Tubeimoside I improves endothelial function in sepsis via activation of SIRT3. | Yang, X., et al. 2021. Lab Invest. 101: 897-907. PMID: 33664465
- A novel cell culture system modeling the SARS-CoV-2 life cycle. | Ju, X., et al. 2021. PLoS Pathog. 17: e1009439. PMID: 33711082
- Tubeimoside I protects against sepsis-induced cardiac dysfunction via SIRT3. | Cheng, Z., et al. 2021. Eur J Pharmacol. 905: 174186. PMID: 34033817
- Tubeimoside I Ameliorates Myocardial Ischemia-Reperfusion Injury through SIRT3-Dependent Regulation of Oxidative Stress and Apoptosis. | Lv, D., et al. 2021. Oxid Med Cell Longev. 2021: 5577019. PMID: 34795840
- Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. | Tang, Q., et al. 2022. Phytomedicine. 99: 154016. PMID: 35278900
- Tubeimoside I Ameliorates Doxorubicin-Induced Cardiotoxicity by Upregulating SIRT3. | Zhang, W., et al. 2023. Oxid Med Cell Longev. 2023: 9966355. PMID: 36691640
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tubeimoside I, 10 mg | sc-204931 | 10 mg | $98.00 | |||
Tubeimoside I, 25 mg | sc-204931A | 25 mg | $197.00 |